Charles River Laboratories International (CRL) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$4.0B

Revenue (quarter)

$1.0B

Revenue growth (year over year)

−2.72%

Gross profit (trailing twelve months)

$1.3B

Gross margin

32.67%

Net income (trailing twelve months)

−$236.3M

Net income (quarter)

−$760,000.00

Net income growth (year over year)

−101.44%

Net margin

−5.91%

Return on equity

−7.65%

EPS (trailing twelve months)

−$4.81

Book value per share

$60.39

P/E (trailing twelve months)

—

Price to book

4.94

Debt to assets

61.65%

Payout ratio

—

Dividend yield

—

Company profile

Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.

• Is Charles River Laboratories International (CRL) profitable?

  No. Charles River Laboratories International reported a net loss of $236.3M over the trailing twelve months.

• How much revenue does Charles River Laboratories International (CRL) make?

  Charles River Laboratories International generated $4.0B in revenue over the trailing twelve months, down 2.72% year over year.

• How do I buy stock in Charles River Laboratories International (CRL)?

  CRL trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web at Light Horse Dashboard, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.